Diabetic macular edema

This study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks to people with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME). The goal is to see if this dosing schedule is safe and works well for those who have a…

Researchers are testing two doses of an experimental eye implant called EC-104 against the standard Ozurdex implant in adults with diabetic macular edema. The trial enrolls people whose swelling did not improve enough with anti-VEGF injections but who have tolerated steroid eye t…

This study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…

This phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …

This early-stage study tests a new drug, RO7497372, given as an eye injection for people with diabetic macular edema (DME), a condition that causes vision loss. The trial involves 151 participants and aims to check the drug's safety, how long it stays in the eye and blood, and it…

This study tests a drug called faricimab (VABYSMO) in 218 people with diabetic macular edema who have not been treated before. The participants are Black/African American, Hispanic/Latino American, Native American/Alaska Native/Native Hawaiian/Pacific Islander, or Asian Indian. T…

This phase 2 trial tests a gene therapy called 4D-150 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The study involves 72 adults who will receive either the gene therapy or standard aflibercept injections. The goal is to see if a single …

This study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a common cause of vision loss in diabetes. About 1,054 participants receive injections into the eye every 4 weeks for a year, then l…

This study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 984 participants will receive injections into the eye every 4 weeks for a yea…

This phase 2 trial tests RGX-314, a gene therapy given as a single injection into the eye, for people with diabetic retinopathy. The goal is to see if it can improve vision and reduce the need for frequent anti-VEGF injections. About 139 adults with diabetes-related eye damage ar…

This study is a long-term follow-up for people who previously received an injection of RGX-314, a gene therapy, for diabetic retinopathy (with or without diabetic macular edema). The purpose is to monitor the safety and effectiveness of the treatment over a total of five years af…

This study tests a small, refillable implant placed in the eye that delivers medication every 24 weeks, compared to standard monthly eye injections. It includes about 634 adults with diabetic macular edema, a condition that causes vision loss. The goal is to see if the implant wo…

This study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active c…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This study compares two ways of giving faricimab, a drug injected into the eye, to treat diabetic macular edema (DME). One group gets injections on a fixed monthly schedule, while the other uses a 'treat and extend' approach where the time between injections is gradually lengthen…

This Phase 2 trial tests whether the oral drug tonabersat can reduce retinal swelling in people with diabetic macular edema who still have good vision. About 128 adults with type 1 or 2 diabetes will take either tonabersat or a placebo daily for several months. The main goal is t…

This Phase 2 trial tests whether KHK4951 eye drops can improve vision in people with diabetic macular edema (DME), a leading cause of blindness. About 150 participants will receive either the eye drops or standard injections. The goal is to see if the drops can reduce swelling an…

This study compares a new numbing gel (chloroprocaine HCl 3%) to standard eye drops plus a shot for pain relief during eye injections. About 236 adults with conditions like diabetic macular edema or age-related macular degeneration will take part. The goal is to see if the gel wo…

This study compares two common eye injection drugs, aflibercept and bevacizumab, in adults aged 30-60 with diabetic macular edema (fluid buildup in the retina causing vision loss). About 116 participants will receive monthly injections for two months. The goal is to see which dru…

This study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…

This study will use artificial intelligence (AI) to analyze eye scans from 554 adults with diabetic macular edema (DME). The goal is to see if AI can predict when a person's eye treatment needs to change. Participants will not receive any new treatment; instead, researchers will …

This study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and ho…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…

This observational study will follow 2,500 adults with vision loss from nAMD or DME who are already prescribed aflibercept 8 mg by their doctors. Researchers will collect data from routine visits over up to 24 months to see how vision changes. The goal is to understand how well t…

This observational study examines how aflibercept 8 mg, an injection into the eye, is used in routine care for patients in Japan with age-related macular degeneration or diabetic macular edema. Researchers will analyze claims data from about 3000 patients to understand patient ch…

This study follows 110 adults with diabetic macular edema who are prescribed OZURDEX (a dexamethasone implant placed in the eye) by their doctors in routine Chinese clinics. Researchers will track side effects like cataracts, high eye pressure, and bleeding over two years. The go…